Global Gonorrhea Therapeutics Market – A Report by Fact.MR
Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global gonorrhea therapeutics market. The gonorrhea therapeutics market report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth. Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the gonorrhea therapeutics market report elaborates the market behavior of each vendor operating in the gonorrhea therapeutics market.
According to a new study of Fact.MR, the gonorrhea therapeutics market will reach ~US$ 970 Mn in 2019, and estimated to register a 4% Y-o-Y over 2018. The gonorrhea therapeutics industry will remain influenced by increased attention on new developments in novel therapeutic compounds or antimicrobials for improving the success potential of future treatment.
There has been a significant rise in the prevalence of gonorrhea that is resistant to components of dual antibiotic therapy – ceftriaxone and azithromycin, which is the only recommended treatment for gonorrhea. In addition, resistance to several other antibiotics apart from dual antibiotic therapy resulted in ‘super gonorrhea’, which has become a buzzword in the gonorrhea therapeutics market. With a slew of promising new antibiotics on the horizon, alongside surveillance, education and preventative measures to stymie prevalence of super-resistant gonorrhea, prospects seem bullish for the gonorrhea therapeutics market.
The gonorrhea therapeutics market report considers the following years to present the overall market growth:
- History Year: 2014 – 2018
- Base Year: 2014
- Estimated Year: 2029
- Forecast Year: 2019 – 2029
Key findings of the gonorrhea therapeutics market study:
- Regional breakdown of the gonorrhea therapeutics market based on predefined taxonomy.
- Innovative manufacturing processes implemented by gonorrhea therapeutics market vendors in detail.
- Region-wise and country-wise fragmentation of the gonorrhea therapeutics market to grasp the revenue, and growth outlook in these areas.
- Changing preferences among consumers across various regions and countries.
- Factors (Positive and Negative) impacting the growth of the global gonorrhea therapeutics market.
Want to know more about the report or any specific requirement: https://www.factmr.com/connectus/sample?flag=AE&rep_id=3761
On the basis of drug type, the gonorrhea therapeutics market study consists of:
- Macrolide Antibiotics (Azithromycin)
- Third-Generation Cephalosporin
- Tetracycline Antibiotics (Doxycycline)
- Fluoroquinolones Antibiotics (Gemifloxacin)
- Aminoglycoside (Gentamicin)
- Aminocyclitol (Spectinomycin)
The market of gonorrhea therapeutics is likely to grow in parallel with the potentially effective drugs that are currently in pipeline. Growing number of clinical trials and rising investments in healthcare industry will continue to pave lucrative avenues of growth for the gonorrhea therapeutics market. The study opines that dual therapy will remain the treatment of choice for gonorrhea, accounting for ~90% market shares. This falls in line with the current recommended regimen for gonorrhea treatment that includes a combination of two antibiotics, azithromycin, which is given orally, and ceftriaxone, an intra-muscular drug.
According to the study, azithromycin will continue to account for greater gains in the gonorrhea treatment market, closely trailed by the third-generation cephalosporin that are increasing gaining traction. Azithromycin sales for the treatment of gonorrhea are expected to hold ~50% market shares. Sales of third-generation cephalosporin are expected to grow at a rate similar to that of azithromycin in the foreseeable future. As some countries turn to increasing the doses of the recommended gonorrhea drugs in an attempt to overcome the bacteria’s resistance, the demand for macrolide antibiotics and third-generation cephalosporin is likely to grow steadily in coming years.
According to the Fact.MR study, lucrativeness of developed markets – North America and Europe – for gonorrhea therapeutics will endure, primarily underpinned by growing prevalence of STDs and rapidly advancing healthcare infrastructure in these regions. In the US alone, ~1 Mn cases of gonorrhea are reported annually, according to recent studies. Favorable reimbursement policies and government funding to numerous health organizations for the development of drug-resistant gonorrhea treatment will remain the key growth influencers of the market in these regions.
On the basis of region, the gonorrhea therapeutics market study contains:
- North America (U.S., Canada)
- Latin America (Brazil, Mexico)
- Europe (U.K., Germany)
- APEJ (China, India)
Key players analyzed in the gonorrhea therapeutics market study:
- Merck & Co.
- Hoffmann-La Roche Ltd.
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sanofi S.A.
- Novartis AG.
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Allergan plc
Queries addressed in the gonorrhea therapeutics market report:
- How has the global gonorrhea therapeutics market grown over the historic p